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ABSTRACT 
Identification of recurrent tumour-specific chromosomal translocations and novel fusion 
oncogenes has important diagnostic, therapeutic, and prognostic implications. Over the past 
decade, fluorescence in situ hybridization (FISH) analysis of tumour samples has been one of the 
most rapidly growing areas in genomic medicine and surgical pathology practice. Unlike 
traditional cytogenetics, FISH affords a rapid analysis of formalin-fixed, paraffin-embedded cells 
within a routine pathology practice workflow. As more diagnostic and treatment decisions are 
based on results of FISH, demand for the technology will become more widespread. Common 
FISH-detected alterations are chromosome deletions, gains, translocations, amplifications, and 
polysomy. These chromosome alterations may have diagnostic and therapeutic implications for 
many tumour types. Integrating genomic testing into cancer treatment decisions poses many 
technical challenges, but rapid progress is being made to overcome these challenges in precision 
medicine. FISH assessment of chromosomal changes relevant to differential diagnosis and 
cancer treatment decisions has become an important tool for the surgical pathologist. The aim of 
this review is to provide a theoretical and practical survey of FISH detected translocations with a 
focus on strategies for clinical application in surgical pathology practice.  
 
Key Words: Fluorescence in situ hybridization (FISH), molecular genetics/cytogenetics, targeted 
therapy, precision medicine, differential diagnosis 
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1. Introduction 
 
In the late 1960s, in situ hybridization was first performed with radioisotope-labeled probes 
followed by autoradiography.[1-3] Fluorescence-labeled probe technology started in the early 
1980s with RNA probes that were directly labeled with fluorophores complementary to specific 
DNA sequences. Advances in fluorescence microscopy and digital imaging, as well as 
widespread availability of genomic and bioinformatic resources, have greatly improved the 
resolution, sensitivity, specificity, and accessibility of fluorescence in situ hybridization (FISH).  
 
Interphase FISH, hereinafter simply referred to as FISH, is the usual clinical application of this 
diagnostic tool.[4]  FISH involves the use of fluorescence labeled fragments of DNA (probes) 
binding to interphase chromosomes of cytology specimens or paraffin embedded tissue sections. 
Common FISH-detected alterations are chromosome deletions, gains, translocations, 
amplifications, and polysomy. These chromosome alterations may have diagnostic and 
therapeutic implications for many tumour types[5, 6]. Integrating precise genomic testing into 
cancer treatment decisions poses many technical challenges, but rapid progress is being made in 
overcoming these difficulties. This review focuses on FISH based detection of translocations 
applicable to surgical pathology. 
 
2. Chromosomal translocations: An overview 
Chromosomal translocation refers to a chromosome rearrangement involving nonhomologous 
chromosome parts. Translocations can be balanced, without net loss of material, or unbalanced, 
with gain or loss of genetic loci. Translocation often creates fusion genes when two otherwise 
separated chromosome parts join.[7-9] These fusion genes may behave as a hybrid chimeric 
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oncogene, inducing tumorigenesis by gene overexpression, or they may interrupt an important 
control region, causing unresponsiveness to regulatory control factors. For example, receptor 
tyrosine kinase gain of function fusion oncogenes are a mechanism whereby mesenchymal cells 
may be transformed into sarcomas. Constitutive activation of the insulin family kinase ALK 
results from unregulated dimerization of the fusion gene protein containing the active ALK 
kinase domain. This mechanism underlies about half of inflammatory myofibroblastic tumours. 
Most Ewing sarcoma cases result from EWSR1-FLI1 gene fusion deregulating the ETS 
transcription factor FLI1, leading to aberrant expression of Ewing sarcoma transforming genes. 
The pathognomonic fusion protein of dermatofibrosarcoma protuberans (DFSP) is PDGFB-
COL1A1. This amalgamation of the essential fibroblast collagen gene (COL1A1) with the 
angiogenic growth factor gene (PDGFB) leads to increased growth factor release. An 
overabundance of growth factor results in overstimulation of receptor tyrosine kinase PDGFR, 
activating not only endothelial cells but also fibroblasts and inflammatory cells.[10]  
 
Translocations may involve two different chromosomes or may exchange information between 
regions in the same chromosome. Intrachromosomal rearrangement may cause transposition of 
the involved loci with or without centromere involvement. Chromosome rearrangement, whether 
intrachromosomal or between chromosomes, invariably leads to a neoteric juxtaposition of 
previously unrelated gene elements into a new fusion gene that may or may not be transcribed. 
Fusion gene detection, therefore, is at the heart of FISH diagnostic testing.  
 
Chromosomal translocation is detectable by several methods, including FISH, metaphase 
karyotyping, microarray comparative genomic hybridization, SNP-array, and next generation 
sequencing[10-20]. Some chromosomal translocations are not detectable by FISH, whether by split-
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apart ( Some chromosomal translocations are not detectable by FISH, whether by split-apart (Fig. 
1) or by fusion probes (Fig. 2). To be a reliable diagnostic tool, the probe sets must reproducibly 
show either an increase or a decrease in the optical distance between probe signals. Some 
translocations, especially those involving intrachromosomal inversion or deletion, have a 
relatively short physical distance between the fusion partners after translocation. These small 
distances cannot reliably be resolved at the light microscopic level. In this scenario, a PCR-based 
method is favoured. RNA-seq, a next generation sequencing technique, can detect both known 
and novel gene fusion events and allows RNA analysis through cDNA sequencing at a 
comprehensive genome-wide scale. It can detect both cryptic intrachromosomal rearrangements 
and some fusion products with uncharacterized fusion partners[14, 21-26]. (Fig. 1) or by fusion 
probes (Fig. 2). To be a reliable diagnostic tool, the probe sets must reproducibly show either 
increased or decreased the optical distance between probe signals. Some translocations, 
especially those involving intrachromosomal inversion or deletion, have a relatively short 
physical distance between the fusion partners after translocation. These small distances cannot 
reliably be resolved at the light microscopic level. In this scenario, a PCR-based method is 
favored. RNA-seq, a next generation sequencing technique, can detect both known and novel 
gene fusion events and allow RNA analysis through cDNA sequencing at a comprehensive 
genome-wide scale. It can detect both cryptic intrachromosomal rearrangements and some fusion 
products with uncharacterized fusion partners.  
 
3. Chromosomal translocations mainly associated with sarcomas 
About 30% of sarcomas have well documented specific translocations, and the percentage 
continues to grow. With some exceptions, sarcoma translocations form fusion genes with the 5′ 
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gene segment contributing a strong promoter and overexpression of the 3′ proto-oncogene 
segment by transactivation. Recurrent gene fusions in soft tissue sarcomas tend to occur in 
tumours sharing similar morphological characteristics.[27] Roughly half of the sarcoma-
associated fusion genes contain a member of the TET gene family, including FUS, EWSR1, and 
TAF15 as the proto-oncogene partner.  Most fusion genes are strongly associated with a 
particular tumour type, potentially making them ideal molecular diagnostic markers.[10, 27-29] 
Some fusion proteins are actual or potential therapeutic targets, making the detection of fusion 
gene products valuable both for diagnostic and for therapeutic purposes. 
 
More than 400 recurring translocations have been found in soft tissue sarcomas. The challenge 
now is to identify which of these recurring translocations truly has diagnostic, mechanistic, or 
therapeutic meaning for the associated sarcomas. Over 30 subtypes of the mesenchymal tumor 
can be confirmed by FISH analysis based on tumor-specific chimeric fusion sequences.[28] 
FISH-identifiable sarcomas include many common entities: Ewing sarcoma/primitive 
neuroectodermal tumor, synovial sarcoma, liposarcoma, round cell Ewing-like sarcoma, 
pulmonary myxoid sarcoma, inflammatory myofibroblastic tumor, and others (Table 1). 
 
3.1 Ewing sarcoma 
Ewing sarcomas are composed of small round blue cells with highly malignant behaviour, 
usually affecting bone and extraosseous tissues of children and young adults. There is a specific 
balanced chromosomal rearrangement in most Ewing sarcomas, providing a valuable tool for 
diagnosis. The fusion partners of EWSR1 belong to several gene families, mainly encoding 
transcription factors. These proteins join the amino terminal of the EWSR1 gene with the carboxy 
terminal of an ETS gene family member. This fusion not only abrogates the RNA splicing 
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function of EWSS1 but also removes essential trans-activating control regions of the ETS gene 
partner. As many as 90% of the translocations involve the EWSR1 gene in the form of 
t(11;22)(q24;q12) translocation, which juxtaposes EWSR1 at 22q12 with the FLI1 gene on 
chromosome 11q24.[30]  
 
The fusion gene encodes a protein containing the upstream amino-terminal domain of EWSR1 
and the downstream carboxy-terminal region of FLI1. This fusion protein uniquely functions in 
controlling cell growth and regulating the transcription of downstream genes responsible for 
uncontrolled cell division, and survival in the face of otherwise lethal additional mutations. The 
ERG translocation, t(21;22)(q22;12), resulting in EWSR1-ERG fusion, represents only 10% of all 
Ewing sarcomas. The functional consequences of these variant fusion proteins are similar to 
those of the more common EWSR1-FLI1 fusion. One study suggested a better outcome for 
patients with localized tumours expressing the most common t(11;22) transcript (EWSR1 exon 7 
fused to FLI1 exon 6), but limited prognostic data is currently available for the less common 
fusion types at this time.[31] 
 
3.2 Myxoid liposarcoma 
The diagnosis of myxoid liposarcoma may be challenging by histology alone, especially on small 
biopsy tissues, since a variety of soft tissue tumours with myxoid change may mimic myxoid 
liposarcoma. Myxoid liposarcoma represents about 10% of all adult sarcomas and approximately 
33% of all liposarcomas. Chromosomal translocations t(12,16)(q13;p11) and t(12;22)(q13;q12), 
rendering gene fusions of DNA-damage inducible transcript 3 (DDIT3) with FUS or EWSR1, 
respectively, are characteristic of myxoid liposarcoma; one of these is identifiable in more than 
Page 7 of 64 The Journal of Pathology: Clinical Research
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
95% of cases. Commonly used FISH probes are included in the Vysis DDIT3 dual colour, break-
apart rearrangement probe kit, t(12;16)(q13;p11).  
 
3.3 Synovial sarcoma 
Synovial sarcoma is characterized by t(X;18)(p11;q11) translocation, which is present in 
virtually all tumours. The translocation fuses synovial sarcoma translocation gene (SS18) on 
chromosome 18 with either synovial sarcoma X breakpoint 1 (SSX1) (66%) or SSX2 (33%), 
located on chromosome Xp11.[32, 33] The FISH test is highly specific and sensitive for synovial 
sarcoma. A characteristic t(X;18)(p11;q11) translocation or variants were found in 90% of 
synovial sarcomas. The t(X;18) translocation has not been found in other sarcomas.  
 
3.4 Solitary fibrous tumour  
Solitary fibrous tumour comprises a family of soft tissue lesions usually affecting adults, 
occurring at any site, and presumed to be of fibroblastic differentiation. The tumours were 
thought to derive from pericytes, but now there is evidence to support a fibroblastic or 
myofibroblastic origin. Recurrent fusions of the two genes, NGFI-A–binding protein 2 (NAB2) 
and signal transducer and activator of transcription 6 (STAT6), both located near chromosomal 
region 12q13, have been identified in solitary fibrous tumours. The NAB2-STAT6 fusion gene is 
derived from an inverted intrachromosomal fusion of the NAB2 and STAT6 genes on 12q13.[34, 
35] The fusion product contains the activation domain of STAT6 fused to the early growth 
response (EGR)-binding domain of NAB2[36]. Overexpression of the NAB2-STAT6 fusion gene 
induces cell proliferation and activates expression of EGFR-responsive genes. Chmielecki et al 
identified the NAB2-STAT6 translocation by whole exome sequencing of 17 solitary fibrous 
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tumours and matched blood.[34] This fusion gene was confirmed in 29 of 55 (55%) solitary 
fibrous tumours by exome sequencing. Since the NAB2 and STAT6 genes are both located near 
12q13, the break apart designed probe may detect some but not all of the NAB2-STAT6 
translocations. Mohajeri et al used 6 independent molecular genetic techniques directed at NAB2 
or STAT6 rearrangement to identify NAB2–STAT6 fusion in 37 of 41 (90%) of the solitary 
fibrous tumours evaluated.[37]  
 
It should be noted that the NAB2-STAT6 fusion is not consistently detected by FISH due to the 
very close proximity of the 2 genes (overlapping ends)[36] and, in this setting, RT-PCR is the 
preferred method of detection. STAT6 immunostaining is highly sensitive and specific for 
detecting NAB2-STAT6 fusion product and is now becoming standard practice.  
 
3.5 Round cell Ewing-like sarcoma 
There is a small subset of sarcomas that clinically and histologically mimic Ewing sarcoma but 
fail to exhibit any of the cytogenetic abnormalities reported for these tumours. Recently cases of 
“Ewing-like sarcoma” have been found to have a recurrent chromosomal translocation, 
t(4;19)(q35;q13), resulting in fusion of capicua homolog (CIC) and double homeobox 4 
(DUX4).[38] Fusion of the C-terminal fragment of DUX4 with CIC enhances the transcriptional 
activity of CIC and deregulates expression of its downstream targets. CIC-DUX4 fusion protein 
directly binds the ETS variant 5 (ETV5) promoter at a previously unrecognized site and 
upregulates expression of this oncogene. Four cases of CIC-DUX4 sarcoma were identified using 
a combination of conventional cytogenetic, reverse transcription polymerase chain reaction (RT-
PCR), and FISH methods.[39] FISH was positive for CIC-DUX4 fusion in all four tumours. The 
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distinctive histopathological features and rapid disease progression may warrant classification of 
CIC-DUX4 sarcoma as a new translocation-associated sarcoma.  
 
3.6 Inflammatory myofibroblastic tumour 
Inflammatory myofibroblastic tumour is a spindle cell neoplasm most frequently found in the 
urinary bladder but occasionally diagnosed at various body sites. Although these tumours usually 
behave in a benign fashion, they may be difficult to differentiate from sarcoma or sarcomatoid 
carcinoma. Roughly half of inflammatory myofibroblastic tumours have ALK rearrangements 
leading to elevated expression of ALK chimeric protein.[40] The ALK translocations involve 
2p23 with multiple fusion partners, including TPM3-ALK, RANBP2-ALK, TPM4-ALK, EML4-
ALK, CLTC-ALK, CARS-ALK, ATIC-ALK, SEC31A-ALK, and PPFIBP1-ALK.[41, 42] In each 
instance, the fusion gene overexpresses ALK due to promoter swapping. ALK rearrangements 
may prove useful for distinguishing inflammatory myofibroblastic tumour from morphologically 
similar neoplasms. 
 
Therapy targeting tumour cells with ALK gene rearrangement has been shown to induce partial 
tumour remission.[43, 44] Currently, little is known about the pathogenesis of the 50% of 
inflammatory myofibroblastic tumours that lack ALK translocation.  
 
Besides ALK, ROS1 and NTRK3 gene rearrangements, YWHAE–ROS1 and ETV6–NTRK3 are 
also found in ALK fusion negative inflammatory myofibroblastic tumours.[45] Antonescu et al 
reported six (10%) ROS1 related translocations in a group of 62 cases. Most of the patients were 
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children, and the tumours were located in the lung or abdomen.[46] Two (3.2%) inflammatory 
myofibroblastic tumour cases showed TFG-ROS1 fusions, t(3;6)(q12;q22).  
 
3.7 Alveolar soft part sarcoma 
Alveolar soft part sarcoma has a characteristic histopathology but a controversial histogenesis.  
Alveolar soft part sarcomas arising in many body sites have a diagnostic translocation. The 
rearrangement involves the alveolar soft part sarcoma locus (ASPSCR1) located on chromosome 
17q25 and the transcription factor for the immunoglobulin heavy chain enhancer 3 (TFE3) gene, 
located on chromosome Xp11.[47] The fusion protein is capable of inducing aberrant 
transcription of TFE3-regulated genes and may confer resistance to cell-cycle arrest signals and 
override arrest. Selvarajah et al investigated 17 alveolar soft part sarcomas from 11 patients by 
array comparative genomic hybridization and FISH. FISH identified the ASPSCR1-TFE3 fusion 
in all cases.[12]  
 
The TFE3-ASPSCR1 [der(17)t(X;17)(p11;q25)] translocation is found in 80% of alveolar soft 
part sarcomas. This translocation is also found in a distinctive subset of renal cell carcinoma 
(translocation renal cell carcinoma) which frequently has a papillary architecture.  
 
3.8 Alveolar Rhabdomyosarcoma  
Alveolar rhabdomyosarcoma (ARMS) is a highly aggressive soft tissue sarcoma associated with 
translocations involving PAX3-FOXO1 [t(2;13)(q35;q14)] or PAX7-FOXO1 [t(1;13)(p36;q14)] 
reportedly accounting for 55-80% and 15-22% of ARMS, respectively.[48] These translocations 
generate fusion proteins that function as transcriptional activators with oncogenic effects. FISH 
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testing has higher sensitivity and specificity than RT-PCR assay for these fusion transcripts.[49]  
FISH analysis using the FOXO1split-apart probe adds the ability to detect variant FOXO1 
rearrangements not detectable by PCR. 
 
3.9 Clear cell sarcoma of soft tissue 
Clear cell sarcoma of soft tissue is a rare mesenchymal malignancy mainly occurring in young to 
middle-aged adults of either sex, typically in the soft tissue of the lower extremities. The tumour 
is aggressive with a high frequency of local recurrence and distant metastasis. Almost all (90%) 
clear cell sarcomas are associated with EWSR1-ATF1 translocation, t(12;22)(q13;q12), while a 
smaller subset of tumours (6%) bear an EWSR1-CREB1 translocation.[50] The specific 
translocation is unrelated to tumour prognosis. In a group of 33 clear cell sarcomas, RT-PCR 
using RNA extracted from formalin-fixed, paraffin-embedded tissues demonstrated transcripts of 
the EWSR1-ATF1 (31/33) or EWSR1-CREB1 fusion gene (2/33).[51] 
 
4. Chromosomal translocations in other solid tumours 
A growing number of fusion oncogenes have been also associated with some common adult 
epithelial cancers, such as adenocarcinomas of the lung, prostate, colon, kidney, breast, and other 
epithelial solid tumours (Table 2). 
 
4.1  Chromosomal translocations mainly associated with lung cancer 
4.1.1 EML4-ALK translocation 
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase member of the insulin receptor 
superfamily normally expressed only in certain neurons of the developing central nervous 
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system. Fusions of ALK with echinoderm microtubule-associated protein-like 4 (EML4), a 
protein involved in microtubule assembly, results in constitutive activation of the ALK 
kinase.[52, 53]  The ALK fusion oncogene was first identified in anaplastic large-cell lymphoma, 
in which a t(2;5) chromosome rearrangement activates the ALK kinase by fusion with the 
nucleophosmin gene (NPM1) on chromosome 5. ALK fusions have been reported in non-small 
cell lung carcinoma, breast cancer, colorectal cancer, renal cancer, and other tumour types [41, 
42, 54, 55]. The common FISH test for ALK rearrangement uses dual colour labeled probes 
covering the ALK gene and 3′ flanking region of ALK (Fig. 3). The year 2013 was the first time 
that the FDA simultaneously approved a novel anticancer drug (crizotinib, Pfizer) and its 
companion FISH detection kit (ALK FISH probe kit, Abbott Molecular), highlighting the critical 
role of FISH triage for guiding ALK-targeted therapy.[56, 57] A FDA approved Vysis ALK break 
apart FISH probe kit is recommended by the College of American Pathologists (CAP). In 
general, a sample is considered positive if >15% of cells are positive for ALK separation of the 
green and orange signals. 
 
4.1.2 ROS1 translocation 
C-ROS oncogene 1 (ROS1) is a receptor tyrosine kinase of the insulin receptor family. The ROS1 
rearrangements lead to a constitutively activated fusion kinase, and are detected in 1.2–1.7% of 
lung adenocarcinoma cases.[58-60] ROS1 activation stimulates other downstream signaling 
proteins including AKT1, MAPK1, MAPK3, IRS1, and PLCG2.[59] Patients with ROS1 
translocation are significantly younger than most patients with lung cancer and are more likely to 
be never-smokers. Their cancers tend to be adenocarcinoma, and their tumours have a tendency 
towards higher grade. Several genes may serve as fusion partners for ROS1 including SDC4, 
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SLC34A2, CD74, GOPC, and EZR, yet each of the ROS1 fusion products leads to constitutive 
ROS kinase activation.[61]   A dual probe break-apart method is used to detect ROS1 
rearrangement as with ALK rearrangement. Criteria similar to those used for ALK rearrangement 
screening are used to evaluate the ROS1 FISH test.  
 
ROS1 fusions are also found in meningioma, cholangiocarcinoma, and glioblastoma, but no 
systematic investigation of tyrosine kinase inhibitors has been published for ROS1-fusion 
positive tumours of these primary sites.[62, 63] The reported incidence of ROS1 translocation is 
also low in other tumour types: 8.7% (2/23) of cholangiocarcinomas, 0.5% (1/200) of ovarian 
carcinomas, 0.6% (3/495) of gastric adenocarcinomas, 0.8% (2/236) of colorectal carcinomas, 
7.7% (2/26) of inflammatory myofibroblastic tumours, 2.9% (1/34) of angiosarcomas, and 5% 
(1/20) of epithelioid haemangioendotheliomas.[63-66]  
 
4.1.3 RET translocation 
Novel chromosomal translocations involving the RET tyrosine kinase gene were reported 
recently[61, 67]. The rearranged during transfection (RET) gene belongs to the cadherin 
superfamily, and encodes a cell surface receptor tyrosine kinase that transduces signals for cell 
growth and differentiation[67, 68].  Several RET rearrangements have been identified in non-
small cell lung carcinomas, including KIF5B-RET, CCDC6-RET, NCOA4-RET, and TRIM33-
RET.  
 
RET gene translocation occurs in approximately 1–2% of non-small cell lung carcinomas and 
defines a clinically distinct subset of non-small cell lung carcinomas. Patients with 
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adenocarcinomas with RET fusion tend to be younger than most patients with lung cancer and 
they are more likely to be never-smokers.[69] In a study of 936 patients with non-small cell lung 
carcinoma, the RET fusion gene was exclusively detected in 13 patients (11/633, 1.7% in 
adenocarcinoma; 2/24, 8.3% in adenosquamous cell carcinoma).[70] Of the 13 RET fusion-
positive patients, 9 (69%) had KIF5B-RET, 3 (23%) had CCDC6-RET, and 1 (7.6%) had 
NCOA4-RET fusion. Their tumours tended to be poorly differentiated carcinomas that exhibited 
early lymph node metastasis. Drilon et al found RET fusions in 5 of 31 patients and showed that 
the RET kinase can be effectively inhibited by several small molecule inhibitors.[71] Followup 
imaging conducted after 4 and 12 weeks of therapy confirmed a partial response with a 66% 
decrease in measurable disease in the lungs and pleura.  
 
4.1.4 EWSR1-CREB1 translocation in primary pulmonary myxoid sarcomas  
In the 2015 World Health Organization (WHO) Classification of Tumours of the Lung, Pleura, 
Thymus and Heart, pulmonary myxoid sarcoma with EWSR1-CREB1 translocation was 
introduced as a new entity.[72] Primary pulmonary myxoid sarcoma is rare, and arises most 
frequently in young females.  The tumour consists of lobules with delicate, lacelike strands and 
cords of mildly atypical round or spindle cells in a prominent myxoid stroma. In addition to 
displaying a distinct morphology, it bears a EWSR1-CREB1 translocation in 70% of cases.[73]  It 
should be noted that EWSR1-CREB1 translocation is not unique for this entity; it can also be 
observed in clear cell sarcoma-like tumour of the gastrointestinal tract and angiomatoid fibrous 
histiocytoma (Table 1) 
 
5. Chromosomal translocations mainly associated with kidney cancer 
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5.1 TFE3 translocation 
Renal cell carcinomas associated with Xp11.2 translocation are uncommon renal tumours that 
were recognized as a distinct entity in the 2016 World Health Organization classification of 
Tumours of the Urinary System and Male Genital Organs.[74] These neoplasms comprise the 
majority of paediatric renal cell carcinomas and a smaller percentage of adult renal cell 
carcinomas. There are several different translocations involving chromosome Xp11.2, resulting 
in gene fusions of the TFE3 gene with various activating partners. At least five different fusion 
partners for TFE3 have been characterized, including ASPSCR1, PRCC, SFPQ, CLTC, and 
NONO (Fig. 4).[75, 76] Variant translocations with unknown fusion partners include 
t(X;3)(p11.2;q23) and t(X;10)(11.2;q23). Different gene fusions in Xp11.2 translocation renal 
cell carcinoma may be associated with different morphological features.[77, 78]  
 
The TFE3 break-apart FISH assay has proven useful for detecting TFE3 gene fusions in Xp11.2 
translocation renal cell carcinoma, and the FISH assay, in comparison with 
immunohistochemical evaluation, is less often adversely affected by technical and fixation issues. 
Rao et al analyzed 24 poorly differentiated renal cancers with break-apart TFE3 FISH.[79] 
Seventeen cases showed TFE3 rearrangement associated with Xp11.2 translocation by FISH, 
including seven previously unclassified renal cell tumours, supporting the diagnostic value and 
clinical application of FISH for enigmatic renal tumours. On the basis of commercially available 
and widely tested break-apart FISH assays, the TFE3 split-signal pattern was considered positive 
when ≥10% of the tumour nuclei showed separation of the two coloured signals by more than 
one signal diameter (Fig. 5).  
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5.2 TFEB translocation 
The t(6;11) translocation renal cell carcinoma is rare and usually bears a translocation between 
TFEB and MALAT1 on chromosome 11q12, but rarely TFEB may partner with KHDRBS2 on 
chromosome 6q11 (Fig. 4B).[80] Renal cell carcinomas with t(6;11)(p21;q12) are characterized 
by translocation involving the transcription factor EB (TFEB). Identification of either TFEB 
protein overexpression or t(6;11) translocation is useful for the diagnosis of TFEB renal cell 
carcinoma. Cytogenetic karyotypic analysis and RT-PCR are also common methodologies for 
identifying this translocation. Unfortunately, these methods are limited by the need for fresh 
viable tumour cells for culture or flash frozen tissue to quantitatively assay TFEB mRNA. More 
recently, a break-apart FISH assay to detect TFEB gene translocation has been validated on 
formalin-fixed paraffin-embedded tissues, and appears to be superior to the TFEB IHC assay. 
Rao et al reported seven patients with TFEB renal cell carcinoma confirmed diagnostically by 
using FISH technology. All seven cases were TFEB positive by both fusion and split-apart probe 
designs.[81]  
 
5.3 SMARCB1/SMARCB1 genetic alterations and ALK translocation  
Renal medullary carcinoma is a rare, aggressive tumour with a poor clinical outcome. It belongs 
to a SMARCB1-deficient tumour family.[82] Inactivation of tumour suppressor gene SMARCB1 
is the hallmark of this tumour. Cheng et al studied a total of 19 renal cancers that included 5 
renal medullary carcinomas, 2 paediatric rhabdoid tumours of kidney, 10 high grade renal cell 
carcinomas, and 2 urothelial carcinomas.[83] All renal medullary carcinomas were from African 
American patients with sickle-cell trait who presented with extensive extrarenal metastases at the 
time of diagnosis. All five renal medullary carcinomas and two renal rhabdoid tumours showed 
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complete loss of SMARCB1 expression. Another study by Calderaro et al found recurrent 
alterations involving chromosome 22q11 in each of four renal medullary carcinomas associated 
with sickle-cell trait. Each of these showed hemizygous SMARCB1 deletion[84].  RNA 
sequencing further identified fusion transcripts involving SMARCB1 in these tumours. The 
transcripts resulted from balanced translocations disrupting SMARCB1 and fusing it to various 
partners including CAPN2, RORA, MAML2, and MALAT1.  
 
ALK translocation was also reported in renal medullary carcinomas from young patients with 
sickle-cell trait to be associated with VCL-ALK translocation.[85] The incidence of ALK 
rearrangement associated with all renal cell carcinomas is low, with an overall frequency of 
<1%. In a study including 534 adult renal cell carcinoma patients, ALK rearrangements occurred 
in two papillary renal cell carcinomas.[86] More recently, Kusano et al reported 2 cases of RCC 
harbouring a novel STRN-ALK fusion.[87] In both cases, the patients were in their 30s at the 
time of nephrectomy. 
 
6.  Chromosomal translocations mainly associated with prostate cancer 
A significant event in prostate carcinogenesis involves gene fusion between members of the E-
twenty-six transforming factor (ETS) family of genes, including ERG, and the transmembrane 
protease, serine 2 (TMPRSS2, 21q22.3) gene[88-91]. The genes involved are the androgen-
regulated gene TMPRSS2 and ETS transcription factor family members, including ERG 
(21q22.2), ETV1 (7p21.2), or ETV4 (17q21). TMPRSS2-ERG gene fusion has been identified in 
about 50% of prostate tumours (ranging from 27% to 79%). These fusions appear to represent a 
specific early event in prostatic carcinogenesis that can be observed in high grade prostatic 
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intraepithelial neoplasia.[90] The TMPRSS2-ERG rearrangement can be identified by both dual 
colour split apart probe or by tricolour probes (Fig. 6).[92-94]  
 
7. Chromosomal translocations mainly associated with breast cancer 
A rare variant of breast cancer, secretory breast cancer, has a characteristic recurrent 
translocation between ETS variant 6 (ETV6) and neurotrophic tyrosine kinase type 3 (NTRK3), 
t(12;15)(p13;q25).[95, 96] This translocation appears to be the initial hit required for formation 
of secretory breast cancer. Retroviral transfer of ETV6-NTRK3 into murine mammary epithelial 
cells resulted in transformed cells that readily formed tumours in nude mice. 
 
The biological consequence of this translocation is expression of a chimeric tyrosine kinase 
protein with potent transforming capability. The fusion protein strongly activates the MAPK1 
and the PIK3CA/AKT1 pathways.[96] The occurrence of the ETV6-NTRK3 translocation and 
consequential expression of the oncogene is an initiating event in the genesis of secretory breast 
cancer.[97]  The ETV6-NTRK3 translocation is demonstrated either by break-apart or by fusion 
FISH design. Positive signal patterns have been seen in most secretory breast carcinoma tumour 
cells using either assay strategy.  
 
8. Chromosomal translocations mainly associated with colorectal cancer 
The first recurrent fusion gene in colorectal cancer was reported in 2011.[98] Bass et al 
correlated the genomes of nine colorectal cancers with paired non-neoplastic tissue controls. 
Recurrent VTI1A-TCF7L2 fusion was identified in 3% of colorectal cancers.[98] Their findings 
indicated that functionally important fusion events also occur in colorectal cancers, but the 
Page 19 of 64 The Journal of Pathology: Clinical Research
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
clinical impact of these is yet to be elucidated.  RNA-sequencing studies reported by Seshagiri et 
al identified multiple fusion transcripts in colorectal cancer, including recurrent gene fusions 
involving R-spondin family members EIF3E-RSPO2 and PTPRK-RSPO3 that occurred with a 
cumulative frequency of 10% in colorectal cancers.[99] Other translocations reported in recent 
years include EML4-ALK, C2orf44-ALK, SLC34A2-ROS1, and NAV2-TCF7L1.[66]  
 
9. Chromosomal translocations mainly associated with thyroid cancer 
More than 10 rearrangements involving RET have been reported; all of the rearrangements are 
formed by fusion of the RET tyrosine kinase domain with a fusion partner gene [100-103]. RET 
rearrangements have been identified almost exclusively in papillary thyroid carcinomas; most 
frequent were RET-CCDC6 (60%), RET-NCOA4 (20%) and RET- PRKAR1A (5-12%)[67, 68, 
104]. The fusion genes code for constitutively activated proteins driving uncontrolled 
proliferation of follicular cells.  
 
Kelly et al reported that STRN-ALK fusion occurs in a subset of patients with highly aggressive 
types of thyroid cancer and provide initial evidence suggesting that it may represent a therapeutic 
target for these patients. STRN-ALK fusion protein leads to constitutive activation of ALK 
kinase.[105]  
 
Follicular thyroid carcinoma accounts for approximately 20% of all thyroid malignancies. The 
t(2;3)(q13;p25) translocation, fusion of the thyroid transcription factor, paired box gene 8 
(PAX8)  with peroxisome proliferator activated receptor γ (PPARG) is most commonly observed 
(30%) in follicular thyroid carcinoma.[106] The fusion product acts as an oncogene by 
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accelerating cellular growth, down-regulating apoptosis, promoting anchorage-independence, 
and causing loss of contact inhibition. It is noteworthy that rearrangement of these genes has also 
been identified in benign thyroid adenomas with a break-apart frequency between 3% and 
6%.[107, 108] 
 
10. Chromosomal translocations mainly associated with salivary gland 
tumours 
Approximately 20% of salivary gland tumours harbour chromosomal translocation.[109]  There 
are four major recurrent translocations in malignant salivary gland tumours: the MYB-NFIB 
fusion in adenoid cystic carcinoma, the CRTC1-MAML2 fusion in mucoepidermoid carcinoma, 
the ETV6-NTRK3 fusion in mammary analogue secretory carcinoma, and the EWSR1-ATF1 
fusion in hyalinizing clear cell carcinoma (Table 2)[96, 97, 110, 111]. The identification of 
recurrent tumour-specific chromosomal translocations and novel fusion oncogenes has 
diagnostic, therapeutic, and prognostic implications.  
 
10.1 Pleomorphic adenoma 
Pleomorphic adenoma is a benign salivary gland tumour most often arising in the parotid gland. 
The tumour presents with a highly specific and recurrent pattern of chromosome abnormalities in 
70% of cases. There are four cytogenetic categories of pleomorphic adenoma. These involve 
8q12 (39%), 12q13-15 (8%), other recurring translocations (23%), and cytogenetically 
unchanged cases (30%). Of cases with rearrangements, the 8q12 rearrangement 
[t(3;8)(p21;q12)], represents almost half of the diagnostic translocations found.  
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10.2 Mucoepidermoid carcinoma 
Mucoepidermoid carcinoma represents a distinct type of polymorphous tumour, containing three 
cellular elements in varying proportions: squamous cells, mucus-secreting cells, and 
"intermediate" cells. The CRTC1-MAML2 fusion is present in 55% of mucoepidermoid 
carcinomas. The fusion oncogene derived from chromosomal translocation that binds cyclic-
AMP response element protein related transcription co-factor 1 (CRTC1) with mastermind-like 2 
NOTCH signaling coactivator (MAML2), t(11;19)(q12;p13) is aetiological for some 
mucoepidermoid carcinomas. When present, this marker confers a favourable survival outcome 
when compared with fusion-negative tumours.[112] 
 
10.3 Adenoid cystic carcinoma 
Recurrent t(6;9)(q22–23;p23–24) translocation in adenoid cystic carcinoma results in a fusion of 
the MYB proto-oncogene with transcription factor gene NFIB[113]. MYB is a leucine zipper 
transcription factor at 6q22-24 that participates in the regulation of cell proliferation, apoptosis, 
and differentiation.[114] West et al used FISH to investigate MYB translocation in 37 of these 
tumors. MYB-NFIB translocation was present in 49% of adenoid cystic carcinomas but not in 
other salivary gland tumours or non-salivary gland neoplasms.[115] A subset of about 20% of 
adenoid cyst carcinomas lacks any detectable MYB gene fusion.[116, 117] The high frequency of 
this fusion in adenoid cystic carcinoma indicates that the transcript may play a developmental 
role in a significant subset of these tumours. Therapies directed against MYB-NFIB 
transcriptional targets may improve the prognosis for this chemoresistant neoplasm.  
 
10.4 Mammary analogue secretory carcinoma 
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Mammary analogue secretory carcinoma (MASC) is a recently recognized salivary gland tumour 
that is histologically, immunohistochemically, and genetically similar to secretory carcinoma of 
the breast.[118] MASC harbours a t(12;15) (p13;q25) translocation resulting in fusion of an E-
twenty-six family member (ETV6) and the neurotrophic tyrosine kinase receptor type 3 (NTRK3) 
gene.[119] Histologically, conventional MASC displays a lobulated growth pattern of a tumour 
composed of microcystic, tubular, and solid structures. Between epithelial structures, one finds 
abundant eosinophilic homogenous or bubbly secretions. Majewska et al investigated seven 
MASC by FISH, and the ETV6-NTRK3 rearrangement was identified in six cases.[120] For FISH 
analysis, a dual-colour break-apart probe for the ETV6 gene exhibits a “split” fluorescent signal 
in nuclei where the ETV6 gene participates in translocation. MASC behaves as a low-grade 
carcinoma with 15–20% recurrence, lymph node metastases in 15–20% of cases, and occasional 
mortality.[118, 121] ETV6 FISH is useful to diagnose difficult cases and to exclude the tumours 
that morphologically mimic MASC. 
 
10.5 Hyalinizing clear cell carcinoma 
Hyalinizing clear cell carcinoma (HCCC) is a recently described minor salivary gland tumour 
composed of glycogen-rich clear cells with hyalinized or myxoid stroma. Gene fusion between 
Ewing sarcoma breakpoint region 1 (EWSR1) and the activating transcription factor 1 (ATF1) 
gene is a relatively consistent finding in hyalinizing clear cell carcinoma.[122] However, 
EWSR1-ATF1 translocation could also be found in other types of tumour including angiomatoid 
fibrous histiocytoma, angiosarcoma of the parotid gland, clear cell sarcoma of soft tissue, and 
clear cell sarcoma-like tumor from the GI tract.[51, 123-126] In one study, the ATF1 gene 
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translocation was found in 82% of hyalinizing clear cell carcinoma cases, but in none of the 
other tumours in the differential diagnosis.[109]  
 
11. Chromosomal translocations mainly associated with Spitz nevi and 
melanoma 
The genetic underpinnings of Spitz nevi are poorly understood, and alterations in melanoma-
associated oncogenes are typically absent. Spitzoid neoplasms harbour kinase fusions of ROS1 
(17%), NTRK1 (16%), ALK (10%), BRAF (5%), and RET (3%) in a mutually exclusive 
pattern.[127] The chimeric proteins are constitutively activated, which stimulate oncogenic 
signaling and initiate the tumorigenesis. In a study of 140 spitzoid neoplasms, Wiesner et al and 
colleagues demonstrated that kinase fusions were present in 18 of 30 Spitz nevi (60%) and 
within 6 of 8 atypical Spitz tumours (75%). The kinase gene fusions involved ROS1 (26%, 
16/73), ALK (11%, 8/75), NTRK1 (11%, 8/75), BRAF (5%, 4/75), and RET (3%, 2/75). FISH can 
be used as an ancillary tool in the diagnosis of ambiguous melanocyte neoplasms, since Spitz 
nevi are benign and do not require wide excision.[127] 
 
Molecular alterations commonly seen in melanomas are typically absent from Spitz nevi and 
Spitz nevi contain translocations not usually found in melanoma[91, 128-130]. Translocations 
involving BRAF and MET genes have been recently reported in melanoma patients (Table 2). 
BRAF fusion genes characteristically activate the MAPK pathway with transformation abilities 
[131, 132]. This activation of the MAPK pathway renders the tumours potentially sensitive to 
MEK inhibition.   
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MET is a high-affinity tyrosine kinase receptor with functions in angiogenesis, cellular motility, 
growth and invasion.[133] Yeh et al analyzed 1202 equivocal pigmented skin lesions 
representing spitzoid melanoma, Spitz nevi, conventional nevi, deep penetrating nevus-like 
lesions and blue nevi. The patients’ tumours were tested by comparative genomic hybridization. 
MET translocations were found in six melanocytic tumours resulting in the following fusion 
genes: TRIM4-MET, ZKSCAN1-MET, PPFIBP1-MET LRRFIP1-MET, EPS15-MET, and 
DCTN1-MET.[134] MET fusion genes are driven by the promoter of the partner gene and 
express MET without control. 
 
12. Chromosomal translocations mainly associated with tumours of the central 
nervous system 
The WHO 2016 classification of tumours of the central nervous system emphasizes the 
importance of molecular classification.[135] More than 10 translocations have been reported in 
glioblastomas and gene fusions occur in approximately 30-50% of glioblastoma patients (Table 
2).[136-139]  PTPRZ1-MET translocation was detected in 15% of glioblastomas in independent 
cohorts, rendering it the most frequently recurring transcript in glioblastoma. Recently, Bao et al 
investigated 272 gliomas by RNA seq and identified 67 in-frame fusion transcripts, including 
three recurrent fusion transcripts: FGFR3-TACC3, RNF213-SLC26A11,and PTPRZ1-MET.[139]  
Fourteen other rare fusion transcripts containing sequences of genes involved in the canonical 
glioblastoma signaling pathways were also found.  
 
Co-deletion of 1p/19q has been observed in up to 70% of oligodendrogliomas and 50% of mixed 
oligoastrocytomas[140-143]. Deletions of 1p and 19q have been associated with prolonged 
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survival in patients with oligodendrogliomas and mixed oligoastrocytomas. Jenkins et al 
hypothesized that the majority of 1p and 19q deletions in gliomas were derived from a 
translocation t(1;19)(q10;p10), which has  a prevalence of 81% in all 1p/19q deletion cases.[144]  
 
KIAA1549-BRAF translocations are characteristic of pilocytic astrocytoma.[138, 145] The 
translocation was found by whole-genome sequencing of 96 pilocytic astrocytomas.[145] These 
new molecular revelations suggested that BRAF targeted therapy may be applicable in pilocytic 
astrocytomas since the majority of tumours harbour KIAA1549-BRAF fusions (Table 2). 
 
Ependymoma arises from the ependymal cells of the brain and spinal cord. Surgery and 
irradiation are the major treatments for this disease since chemotherapy is ineffective in most 
patients.[146] Parker et al showed that more than two-thirds of supratentorial ependymomas 
contained chromosomal translocations between avian reticuloendotheliosis viral oncogene 
homolog A (RELA) and chromosome 11 open reading frame 95(C11orf95).[147] The resulting 
fusion protein activates NF-κB target genes, transforming the cells.[148] This finding is 
significant not only for understanding the biology of the tumour but also affords potential for an 
effective treatment. 
 
13. Conclusions 
Over the past decade, FISH analysis of neoplasms has become one of the most rapidly growing 
areas in genomic medicine and surgical pathology practice. As more diagnostic and treatment 
algorithms incorporate the results of FISH, demand for the technology will become more 
widespread. Common FISH-detected alterations are chromosome deletions, gains, translocations, 
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amplifications, and polysomy. These chromosome alterations may have diagnostic and 
therapeutic implications for many tumour types. Integrating genomic testing into cancer 
treatment decisions poses many technical challenges, but rapid progress is being made in 
overcoming these precision medicine challenges. Next generation sequencing platforms allow 
detection of fusion genes at both the transcriptional and genomic levels. The rapidly emerging 
RNA sequencing (RNA-seq) technology has empowered an increasing pace of fusion gene 
identification.  RNA-seq is superior to current molecular test methods in its capacity to detect 
gene mutations simultaneously, the precise mapping of break-point and joint sequences, and the 
discovery of cryptic fusions and fusion genes with unknown partners or with short physical 
distance between the fusion partners. FISH assessment of chromosomal changes is a 
continuously evolving technology. Its role in clarifying cancer diagnoses and its contributions to 
the decisions involved in choice of cancer therapy will become ever more important to surgical 
pathologists and the clinicians and patients they serve. 
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Figure Legends  
Figure 1 Break-apart probe design for translocations with multiple fusion partners. A break-
apart probe set is composed of two probes specific for loci physically close to each other on the 
chromosome in their wild type configuration. The wild type signal pattern shows 2 pairs of 
closely approximated or fused signals (A). When translocation occurs involving a breakpoint 
between the two probe sites, the originally juxtaposed loci (fusion signals) split apart (B). The 
beauty of this design is that it detects chromosomal translocation regardless of the fusion partner 
involved. However, the break-apart probe only identifies the breaking away of a gene fragment 
from its original location. It does not determine which chromosome receives the fragment or 
which genes may serve as fusion partners in the new location. 
 
Figure 2 Fusion design for translocation between specific partners. A fusion probe set contains 
two locus-specific probes labeled with different colours targeting the genes known to fuse in 
certain tumours or diseases. The fusion probes identify chromosomal loci far from each other 
either on the same chromosome or on different chromosomes. The wild type configuration shows 
two separated signals resulting from physically separated chromosome loci (A). When fusion 
occurs, the two probes move to a closely approximated position (fusion signal, B). This provides 
direct evidence of a gene fusion with definitive fusion partners identified. 
 
Figure 3 Signal patterns of ALK split-apart probes. The commonly used ALK split-apart FISH 
test uses dual colour labeled probes covering the ALK gene (yellow) and 3’ flanking region of 
ALK (red). When translocation occurs, the normal closely approximated signal pattern separates 
into distinct yellow and red signals (in commercial FISH ALK translocation kits Green and Red 
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signals may be used). Since ALK translocations involve multiple fusion partners, a split-apart 
design ensures that the probe set will uncover ALK translocations with most of the possible 
fusion partners. 
 
Figure 4 Genomic translocation relationships presented by Circos plot. Circos applies a circular 
ideogram displaying relationships between genomic intervals. The Circos plot is a ring 
composed of all chromosomes in proportionate size clockwise from 1 to Y. This graphic 
representation is used to visualize chromosomal translocations associated with a clinical entity. 
A specific translocation is shown with a line connecting the two chromosome partner loci 
involved in each translocation. The chromosomal translocations that may be involved in Xp11 
translocation renal cell carcinomas are shown in A, including inv(X)(p11.2;q12) [NonO-TFE3] 
(Red), t(X;1)(p11.2;p34) [PSF-TEF3] (Gray), t(X;1)(p11.2;q21) [PRCC-TFE3] (Blue), 
t(X;3)(p11.2;q23) [unknown-TFE3] (Black), t(X;10)(p11.2;q23) [unknown-TFE3] (Yellow), 
t(X;17)(p11.2;q23) [CLTC-TFE3] (Magenta), t(X;17)(p11.2;q25) [ASPL-TFE3] (Green), 
t(X;19)(p11.2;q13.1) [unknown-TFE3] (Purple). Translocations involved in TFEB translocation 
renal cell carcinoma are shown in B, t(6;11)(p21;q13) [MALAT1-TFEB] (Blue), t(6;17)(p21;q25) 
[ASPSCR1-TFEB] (Red). 
 
Figure 5 Signal patterns of TFE3 split-apart probes. Renal cell carcinomas associated with 
Xp11.2 translocation involve several different translocations resulting in gene fusions of the 
TFE3 gene with various fusion partners. The break-apart FISH assay uses probes both upstream 
(yellow) and downstream (red) to TFE3 showing different signal patterns in female (A) and male 
(B) patients. A positive result in a female patient shows a fused or closely approximated normal 
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yellow-red signal pair (uninvolved X chromosome) and either a pair of split-apart signals or a 
single yellow or red signal due to section truncation artifact. Because males have only one X-
chromosome, a positive result in a male patient consists either of a pair of split-apart yellow and 
red signals, or of a single yellow or red signal due to section truncation. 
 
Figure 6 Signal patterns of TMPRSS2-ERG translocation by tri-colour split-apart probes. The 
TMPRSS2-ERG tri-colour fused probe uses 3 different colour probes recognizing the up-stream 
end of TMPRSS2 (orange), and both up- and down- stream ends of ERG (yellow, red), 
respectively. The probes hybridizing to the wild type TMPRSS2/ERG loci show the normal co-
localized red-yellow-orange pattern (A). TMPRSS2/ERG loci rearrangement via breaks in both 
ERG and TMPRSS2 genes leads to a red-orange fusion of ERG down-stream signal to the 
TMPRSS2 signal. The ERG up-stream signal may either split from the down-stream sequence as 
in (B), or be deleted entirely as shown with the signal pattern shown in (C).  
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Table 1 Chromosome alterations in mesenchymal and uncertain derivation solid tumours 
 
Tumour Type   Chromosomal Translocation Genes Involved % 
Adipocytic tumours 
Chondroid lipoma t(11;16)(q13;p13) C11orf95-MKL2 75-85 
Lipoma t(3;12)(q27;q14) 
t(12;13)(q13;q14) 
t(3;13)(q27;q14) 
t(Y;12)(q12;q14) 
HMGA2-LPP 
HMGA2-LHFP 
LPP-LHFP 
?-HMGA2 
20–25 
* 
* 
* 
Lipoblastoma t(2;8)(q31;q12) 
t(8;8)(q24;q12) 
t(7;8)(q21;q12) 
t(8;14)(q12;q24) 
COL3A1-PLAG1 
HAS2-PLAG1 
COL1A2-PLAG1 
RAD51B-PLAG1 
50-75 
* 
* 
* 
Spindle cell/ pleomorphic 
lipoma 
- 13/del(13)(q14) 
del(16)(q13) 
RB1 
- 
40–48 
40–50 
Hibernoma del(11)(q13-21) MEN1 66–80 
Atypical lipomatous 
tumour/well differentiated 
liposarcoma 
amp(12)(q14-15) 
Supernumerary ring 
MDM2 
- 
80–90  
75–90 
Myxoid liposarcoma t(12;16)(q13;p11) 
del(10)(q23) 
t(12;22)(q13;q12) 
t(12;22;20)(q13;q12;q11) 
FUS-DDIT3 
PTEN 
EWSR1-DDIT3 
EWSR1-DDIT3  
90–95 
7–12 
* 
* 
Fibroblastic/myofibroblastic tumours 
Nodular fasciitis t(17;22)(p13;q13) MYH9-USP6 90–92 
Elastofibroma amp(X)(q12-q22) - 16–30 
Fibroma of tendon sheath t(2;11)(q31;q12) 
t(9;11)(p24;q13) 
- 
- 
# 
# 
Desmoplastic fibroblastoma t(2;11)(q31;q12) 
t(11;17)(q12;p11) 
- 
- 
# 
# 
Cellular angiofibroma del(13)(q14) RB1, FOXO1 54–80 
Mammary-type 
myofibroblastoma 
del(13)(q14) RB1, FOXO1 70-92 
Tenosynovial giant cell tumour t(1;2)(p13;q37) CSF1-COL6A3 50–80 
Giant cell fibroblastoma t(17;22)(q22;q13) COL1A1-PDGFB 80–92 
Dermatofibrosarcoma 
protuberans 
t(17;22)(q22;q13) 
Supernumerary ring 
COL1A1-PDGFB 
- 
74–90 
50–65 
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Inflammatory myofibroblastic 
tumour 
t(1;2)(q21;p23) 
t(2;19)(p23;p13) 
t(2;17)(p23;q23) 
t(2;11) (p23;p15) 
inv(2)(p23q35) 
t(2;4)(p23;q27) 
t(2;12)(p23;p12) 
t(2;5)(p23;q35) 
t(2;2)(p21;p23) 
t(2;1)(p21;q21) 
t(2;19)(p21;p13) 
t(2;2)(p23;q13) 
 
t(6;3)(q22;q12) 
t(6;17)(q22;p13) 
 
t(5;12)(q32;q13) 
TPM3-ALK 
TPM4-ALK 
CLTC-ALK 
CARS-ALK 
ATIC-ALK 
SEC31A-ALK 
PPFIBP1-ALK 
NPM1-ALK      
EML4-ALK 
TPM3-ALK 
TPM4-ALK 
RANBP2-ALK 
 
TFG-ROS1    
YWHAE-ROS1 
 
NAB2-PDGFRB  
25-30 
 
 
 
 
 
10-20 
 
 
 
 
 
 
6-10 
 
 
* 
Low grade fibromyxoid 
sarcoma 
t(7;16)(q33;p11) 
t(11;16)(p11;p11) 
Supernumerary ring  
FUS-CREB3L2 
FUS-CREB3L1 
- 
60-80 
3-6 
25-42 
Myoinflammatory fibroblastic 
sarcoma 
t(1;10)(p22;q24) 
amp(3)(p12) 
TGFBR3-MGEA5 
VGLL3 
62-80 
37-50 
Infantile fibrosarcoma  t(12 ;15) (p13;q25) ETV6-NTRK3 75-90 
Solitary fibrous tumour inv(12)(q13q13) NAB2-STAT6 44-55  
Congenital fibrosarcoma t(12;15)(p13;q25) ETV6-NTRK3 90-99 
Sclerosing epithelioid 
fibrosarcoma  
t(11;22)(p11;q12) 
 t(12;16)(q13;p11) 
t(7;16)(q33;p11) 
t(11;16)(P13;p11) 
EWSR1-CREB3L1 
DDIT3-FUS 
FUS-CREB3L2 
FUS-CREB3L1 
80-90 
10-20 
* 
* 
So-called Fibrohistiocytic tumours 
Tenosynovial giant cell tumour t(1;2)(p11;q35-36) CSF1-COL6A3 50-64 
Epithelioid fibrous histiocytoma t(2;10)(q22;p22) 
t(2;5)(p23;q35) 
VCL-ALK  
SQSTM1-ALK 
80-88 
* 
Smooth muscle tumours 
Benign metastasizing 
leiomyoma 
del(19)(q13.3), del(22)(q12) - #  
Uterine leiomyoma t(12;14)(q14;q22) HMGA2-ALDH2 17-20 
Pericytic (perivascular) tumour 
Myopericytoma t(7;12)(p22;q13) ACTB-GLI1 #  
Skeletal muscle tumours 
Embryonal 
rhabdomyosarcoma 
del(11)(p15.5) IGF2, H19, CDKN1C, 
HOTS 
35-45 
Alveolar rhabdomyosarcoma t(2;13)(q35;q14) 
t(1;13)(p36;q14) 
t(2;2)(q35;p23) 
t(2;8)(q35;q13) 
 
amp(12)(q13-15) 
amp(2)(p24) 
PAX3-FOXO1 
PAX7-FOXO1 
PAX3-NCOA1 
PAX3-NCOA2 
 
GLI1, CDK4, MDM2 
MYCN 
60-85 
15-20 
10-18 
* 
 
22-56 
16-50 
Vascular tumours 
Epithelioid haemangioma t(1;3)(p36;q25) 
t(X;11)(p11;q22) 
t(19;19)(q13;q13) 
t(19;1)(q13;q22) 
WWTR1-CAMTA1 
YAP1-TFE3 
ZFP36-FOSB 
FOS-LMNA 
70-90 
* 
* 
* 
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t(19;10)(q13;p13) FOS-VIM * 
Pseudomyogenic 
haemangioendothelioma 
t(7;19)(q22;q13) 
 
SERPINE1-FOSB 
 
20-30 
 
Epithelioid 
hemangioendothelioma 
t(11;X)(q22;p11)  
t(1;3)(p36;q23) 
YAP1-TFE3 
WWTR1-CAMTA1 
80-94 
77-85 
Chondro-osseous tumours 
Chondromyxoid fibroma inv(6)(p25q13) 
 
del(6)(q24) 
 
t(6;17)(q23;p13) 
t(6;9)(q25;q22) 
- 
 
- 
 
BCLAF1-RAP1GAP2 
COL12A1-? 
75-80 
 
20-40 
 
15-20 
6-20 
Mesenchymal chondrosarcoma del(8)(q13;q21)/t(8;8)(q21;q13) HEY1-NCOA2 70-80 
Nerve sheath tumour 
Melanotic schwannoma del(2)(p16)/amp(2)(p16) CNC2 70-80 
Perineurioma - 22/del(22)(q12) 
Supernumerary ring 
NF2 
- 
75-80 
 
Schwannoma - 22q NF2, SMARCB1 40 
Ewing sarcoma 
Ewing sarcoma t(11;22)(q24;q12) 
t(21;22)(q22;q12) 
t(7;22)(p2;q12) 
t(17;22)(q21;q12) 
t(2;22)(q35;q12) 
t(20;22)(q13;q12) 
inv(22)(q12q12) 
t(4;22)(q31;q12)  
t(6;22)(p21;q12) 
t(2;22)(q31;q12) 
t(1;22)(p36;q12) 
 
t(16;21)(p11;q22) 
t(2;16)(q35;p11)  
 
del(9)(p21) 
t(4;19)(q35;q13) 
t(X;X)(p11;p11) 
EWSR1-FLI1 
EWSR1-ERG 
EWSR1-ETV1 
WESR1-ETV4 
EWSR1-FEV 
EWSR1-NFATC2  
EWSR1-ZFG 
EWSR1-SMARCA5 
EWSR1-POU5F1 
EWSR1-SP3 
EWSR1-PATZ 
 
FUS-ERG 
FUS-FEV  
 
CDKN2A 
CIC-DUX4 
BCOR-CCNB3 
80-90 
12-15 
5-10 
* 
* 
* 
* 
* 
* 
* 
* 
 
* 
* 
 
* 
* 
* 
Tumours of uncertain differentiation 
Angiomatoid fibrous 
histiocytoma 
t(2;22)(q33;q12) 
t(12;22)(q13;q12)  
t(12;16)(q13;p11) 
EWSR1-CREB1 
EWSR1-ATF1  
FUS-ATF1  
75-85 
10-14 
* 
Extraskeletal myxoid 
chondrosarcoma 
t(9;22)(q22;q12) 
t(9;17)q22;q11) 
t(9;15)(q22;q21) 
t(9;22)(q22;q11)  
t(9;17)(q22;q11)  
t(9;15)(q22;q21)  
t(9;22)(q22;q15)  
t(12;22)(q13;q21) 
EWSR1-NR4A3 
TAF2N-NR4A3  
TFC12-NR4A3 
EWSR1-NR4A3  
TAF15-NR4A3  
TCFI2-NR4A3  
TFG-NR4A3 
EWSR1-CHOP 
50-75 
15-20 
* 
* 
* 
* 
* 
* 
Hemosiderotic fibrolipomatous 
tumour 
t(1;10)(p22;q24) TGFBR3-MGEA5 70-85 
Extraskeletal myxoid 
chondrosarcoma 
t(9;22)(q22;q12) 
t(9;17)q22;q11) 
t(9;15)(q22;q21) 
t(9;17)(q22;q11)  
EWSR1-NR4A3 
TAF2N-NR4A3  
TFC12-NR4A3  
TAF15-NR4A3  
50-75 
15-20 
* 
* 
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t(9;22)(q22;q15)  
t(12;22)(q13;q21) 
TFG-NR4A3 
EWSR1-CHOP 
* 
* 
Alveolar soft part sarcoma t(X;17)(p11;q25) ASPSCR1-TFE3 80-95 
Myoepithelioma/myoepithelial 
carcinoma/mixed tumour 
t(6;22)(p21;q12) 
t(1;22)(q23;q12) 
t(1;16)(p34;p11) 
t(9;22)(q33;q21) 
t(19;22)(q13;q12) 
t(12;22)(q13;q12) 
EWSR1-POU5F1 
EWSR1-PBX1 
FUS-KLF17 
EWSR1-PBX3 
EWSR1-ZNF444 
EWSR1-ATF1 
23 
16 
9 
8 
* 
* 
Soft tissue angiofibroma t(5;8)(p15;q13) AHRR-NCOA2 30-50 
Ossifying fibromyxoid tumour t(6;12)(p21;q24) 
t(1;6)(p34;p21) 
t(6;10)(p21;p11)  
t(X;22)(p11;q13) 
EP400-PHF1 
MEAF6-PHF1 
EPC1-PHF1 
ZC3H7B-BCOR  
 
50-80 
 
* 
Clear cell sarcoma of soft tissue t(12;22)(q13;q12) 
t(2;22)(p13;q12) 
t(12;16)(q13;p11) 
EWSR1-ATF1 
EWSR1-CREB1 
FUS-ATF1 
50-75 
6-13 
* 
Clear cell sarcoma of the kidney t(10;17)(q22;p13) YWHAE-NUTM2E 13-25 
Clear cell sarcoma like tumour 
of GI tract 
t(12;22)(q13;q12) 
t(2:22)(q33:q12) 
EWSR1-ATF1 
EWSR1-CREB1 
85-90 
6-20 
Desmoplastic small round cell 
tumour  
t(11;22)(p13;q12) 
t(21;22)(q22;q12) 
EWSR1-WT1  
EWSR1-ERG 
90-99 
* 
Extraskeletal Ewing sarcoma t(11;22)(q24;q12) 
t(17;22)(q12;q12) 
t(21;22)(q22;q12) 
t(7;22)(q22;q12) 
t(2;22)(q36;q12) 
t(16;21)(p11;q22) 
t(2;16)(q36;p11) 
EWSR1-FLI1 
EWSR1-EIAF 
EWSR1-ERG 
EWSR1-ETV1  
EWSR1-FEV 
FUS-ERG 
FUS-FEV 
80-90 
5-10 
* 
* 
* 
* 
* 
Intimal sarcoma amp(12)(q13-14) CDK4, TSPAN31, 
MDM2, GLI 
75-100 
Primary pulmonary 
myxoid sarcoma 
t(2;22)(q33;q12) 
 
EWSR1-CREB1 
 
70-90 
PEComa t(X;17)(p11;p13) 
t(X; 1)(p11;p34) 
inv(X)(p11.2q12) 
 
t(5;8)(q32;q24) 
t(3;3)(p21;p13) 
t(x;14)(q12;q24.1) 
DVL2-TFE3 
SFPQ-TFE3 
NONO-TFE3 
 
HTR4-ST3GAL1 
RASSF1-PDZRN3 
RAD51B-RRAGB 
 
90-100 
 
 
* 
* 
* 
Synovial Sarcoma t(X;18)(p11;q11)  
t(X;18)(p11;q11)  
t(X;18)(p11;q13)  
t(X;20)(p11;q13)  
SYT-SSX1 
SYT-SSX2 
SYT-SSX4 
SS18L1-SSX1 
65-80 
31-35 
* 
* 
Undifferentiated/unclassified sarcoma 
Undifferentiated round and 
spindle cell sarcomas 
t(4;19)(q35;q13.1) 
inv(X)(p11.2p11.4) 
CIC-DUX4 
BCOR-CCNB3 
28-30 
3-12 
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Round cell Ewing-like sarcoma t(4;19)(q35;q13) 
 
t(20;22)(q13;q12) 
t(6;22)(p21;q12) 
t(4;22)(q31;q12) 
inv(22)(q12q12) 
t(4;22)(q31;q12) 
t(1;22)(p36;q12) 
t(2;22)(q31;q12) 
 
t(10;19)(q26;q13) 
t(X;19)(q13;q13) 
 
t(16;21)(p11;q22) 
t(20;16)(q13;p11) 
 
inv(X)(p11.4p11.22) 
 
t(12;15)(p13;q25) 
CIC-DUX4 
 
EWSR1-NFATc2 
EWSR1-POU5F1 
EWSR1-SMARCA5 
EWSR1-PATZ1 
EWSR1-SMARCA5 
EWSR1- ZSG 
EWSR1-SP3 
 
CIC-DUX10 
CIC-FOXO4 
 
FUS-ERG 
FUS-NCATc2 
 
BCOR-CCNB3 
 
ETV6-NTRK3 
60-75 
 
* 
* 
* 
* 
* 
* 
* 
 
* 
* 
 
* 
* 
 
* 
 
* 
Tumour of undefined neoplastic nature 
Aneurysmal bone cyst t(16;17)(q22;p13) CDH11-USP6 66-72 
Data Sources: http://cancer.sanger.ac.uk/cosmic; https://www.mycancergenome.org; http://www.genenames.org; 
http://atlasgeneticsoncology.org; http://cgap.nci.nih.gov/chromosomes; http://www.genecards.org; 
www.tumorfusions.org.   
*Too infrequent to estimate percentage, # limited reports 
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 Table 2 Chromosome alterations in solid tumours of epithelial origin. 
 
Tumour Type Chromosome alteration Gene Involved % 
Head and Neck/Salivary gland 
Pleomorphic adenoma t(3;8)(p21;q12) 
t(5:8)(p13;q12) 
r(8)(p12q12) 
t(8;8)(q12;q12) 
t(8;8)(q11;q12) 
t(7;8)(q21;q12) 
t(8;8)(q24;q12) 
 
t(9;12)(p22;q14) 
t(3;12)(p14;q14) 
CTNNB1-PLAG1 
LFIR-PLAG1 
FGFR1-PLAG1 
CHCHD7-PLAG1 
TCEA1-PLAG1 
COL1A2-PLAG1 
HAS2-PLAG1 
 
HMGA2-NFIB 
 HMGA2-FHIT 
 
 
 
30–40 
 
 
 
 
5-8 
 
Adenoid cystic carcinoma t(6;9)(q22;p23) MYB-NFIB 30–50 
Clear cell odontogenic carcinomas t(22;12)(q12;q13) EWSR1-ATF1 63–82 
Hyalinizing clear cell carcinoma t(22;12)(q12;q13) EWSR1-ATF1 60–85 
Mucoepidermoid carcinoma t(11;19)(q21;p13) 
t(15;11)(q26;q21) 
t(1;11)(q21;q21) 
t(6;22)(p21;q12) 
CRTC1-MAML2 
CRTC3-MAML2  
CRTC2-MAML2 
EWSR1-POU5F1 
50–70 
2–6 
* 
* 
Mammary analogue secretory 
carcinoma 
t(12;15)(p13;q25) ETV6-NTRK3 85–94 
NUT midline carcinoma t(15;19)(q13;p13) 
t(15;9)(q13;q34) 
BRD4–NUTM1 
BRD3-NUTM1 
70–80 
10–15 
Salivary duct carcinoma del(10)(q23) 
 
t(12;8)(q14;q12) 
PTEN  
 
HMGA2-PLAG1 
40–50 
 
22-50 
Solitary dermal cylindroma t(6;12)(q23;q23) MYB–NFIB 60–80 
Squamous cell carcinoma of the head 
and neck 
Amp(8)(p11) FGFR1 9–15 
Thyroid gland 
Papillary thyroid carcinoma inv(10)(q11q21) 
inv(10)(q11q10) 
t(1;15)(q21;q25) 
t(10;17)(q11;q23) 
 
 
t(12;15)(p13;q25) 
 
 
t(10;14)(q11;q32) 
t(7;10)(q32;q11) 
t(10;14)(q11;q32) 
t(1;10)(p13;q11) 
t(10;14)(q11;q22) 
t(8;10)(p21;q11) 
t(6;10)(p21;q11) 
t(8;10)(p11;q11) 
t(10;12)(q11;p13) 
t(10;18)(q11;q21) 
 
t(2;2)(p22;p23) 
t(7;7)(q21;q34) 
RET-CCDC6(PTC1) 
RET-NCOA4(PTC3) 
NTRK1-TPM3 
RET-
PRKAR1A(PTC2) 
 
ETV6-NTRK3
a 
 
 
RET- GOLGA5 
RET-TRIM24 
RET-TRIM27 
RET-TRIM33 
RET-KTN1 
RET-PCM1 
RET-TRIM27 
RET-HOOK3 
RET-ERC1 
RET-MBD1 
 
STRN-ALK 
AKAP9-BRAF 
60-70 
22-30
a 
12 
5-11
a 
 
 
2-14
a 
 
 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
 
* 
* 
Follicular thyroid carcinoma t(2;3)(q13;p25) PAX8-PPARγ 30-35 
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Medullary thyroid carcinoma  t(10;17)(q11;p13) 
 
RET-MYH13 # 
Lung 
Lung adenocarcinoma inv(2)(p21p23) 
t(2;3)(p23;q12) 
t(2;10)(p23;p11) 
t(2;14)(p23;q32) 
t(2;9)(p23;q31) 
t(2;2)(p23;p22) 
t(2;4)(p23;q21) 
t(2;7)(p23;q11) 
 
t(6;10)(q22;q21) 
t(6;7)(q22;p22) 
t(6;12)(q22;q14) 
t(6;20)(q22;q13) 
t(6;5)(q22;q32) 
t(6;19)(q22;q13) 
t(6;6)(q22;q25) 
t(6;1)(q22;q21) 
t(4;6)(p15;q22) 
 
t(1;17)(q23;p11) 
t(1;5)(q23;q33) 
inv(1)(q23q21) 
 
t(10;10)(q11;p11) 
t(10;10)(q11;q21) 
t(10;10)(q11;q11) 
t(1;10)(p13;q11) 
 
t(9;7)(q21;q33) 
EML4-ALK 
TFG-ALK 
KIF5B-ALK 
KLC1-ALK 
PTPN3-ALK 
STRN-ALK 
SEC31A-ALK 
HIP1-ALK 
 
CCDC6-ROS1 
KDELR2-ROS1 
LRIG3-ROS1 
SDC5-ROS1 
CD74-ROS1 
FIG-ROS1 
EZR-ROS1 
TPM3-ROS1 
SLC34A2-ROS1 
 
MPRIP-NTRK1 
CD74-NTRK1 
TPM3-NTRK1 
 
KIF5B-RET 
CCDC6-RET 
NCOA4-RET 
TRIM33-RET  
 
TRIM24-NTRK2 
3-7 
 
 
 
1-2 
 
 
 
 
 
 
 
 
2-3 
 
 
 
 
 
 
1-3 
 
 
 
1 
 
 
 
# 
Primary pulmonary myxoid sarcoma t(2;22)(q33;q12) EWSR1-CREB1 70-90 
Pleura and peritoneum 
Mesothelioma t(14;22)(q23;q12) EWSR1-YY1 * 
Gastrointestinal tract 
Colorectal carcinoma t(6;6)(q22;q22) 
t(11;2)(p15;p11) 
t(2;2)(p23;p23) 
inv(2)(p21p23) 
t(4;6)(p15;q22) 
t(10;10)(q25;q25) 
t(8;8)(q23;q23) 
t(1;1)(q21;q23) 
PTPRK-RSPO3 
EIF3E-RSPO2 
WDCP-ALK 
EML4-ALK 
SLC34A2-ROS1 
NAV2-TCF7L1 
VTI1A-TCF7L2 
NTRK1-TPM3 
5-8 
3-4 
 
2-5 
0.4-0.8 
* 
* 
* 
Esophageal adenocarcinoma t(3;8)(p14.2;q24) FHIT-RNF139 # 
Fibrolamellar hepatocellular 
carcinoma 
t(19;19)(p13.1;p13.2) DNAJB1-PRKACA 92–100  
Intrahepatic cholangiocarcinoma t(1;1)(q23;q25) RABGAP1L-NTRK1 * 
Gynaecological tract 
Endometrial stromal sarcoma t(7;17)(p15;q11) 
t(7;10)(p13;q23) 
t(7;10)(p13;q23) 
 
t(1;6)(p34;p21) 
t(6;7)(p21;p15)  
JAZF1-SUZ12 
YWHAE-NUTM2A 
YWHAE -NUTM2B 
 
MEAF6-PHF1 
JAZF1-PHF1 
40-50 
20-30 
 
 
 
6–10 
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t(6;10)(p21;p11)  EPC1-PHF1  
Ovarian papillary cystadenocarcinoma 
 
t(6;14)(q21;q24) - 32-40 
Breast 
Secretory breast carcinoma t(12;15)(p13;q25) 
t(8;11)(p12;q14) 
t(3;6)(q26;q25) 
 
dic(8;11)(p12;q14) 
ETV6-NTRK3 
TENM4-NRG1 
TBL1XR1-RGS17 
 
TENM4-NRG1 
56–100 
* 
* 
 
* 
Triple-negative breast carcinoma t(1;1)(p13;q44) MAGI3–AKT3 1 
The urinary system and male genital organs 
Oncocytoma t(5;11)(q35;q13) 
t(6;9)(p12;p24) 
- 
- 
#  
#  
Metanephric adenoma t(1;22)(q22;q13) 
t(15;16)(q21;p13) 
t(9;15)(p24;q24)  
inv(12)(q13q15)  
t(1;22)(q22;q13)  
t(15;16)(q21;p13)  
EWSR1-PBX1 
- 
- 
- 
- 
- 
* 
* 
# 
# 
# 
# 
Clear cell renal cell carcinoma del(3)(p11-pter) 
 
 
del(14)(q23) 
VHL, PBRM1, BAP1,  
SETD2 
 
HIF1A 
70–90 
 
 
35–40 
Papillary renal cell carcinoma + 7 
+ 17 
-Y  
MET 
- 
- 
80 
85 
70 
Renal carcinomas associated with 
Xp11.2 translocations 
t(X;1)(p11.2;q21) 
t(X;1)(p11.2;p34) 
t(X;17)(p11.2;q25) 
inv(X)(p11.2q12) 
t(X;17)(p11.2;q23) 
t(X;17)(p11.2;q21.3) 
t(X;19)(p11.2;p13.3) 
PRCC–TFE3 
SFPQ–TFE3 
ASPSCR1–TFE3 
NONO–TFE3 
CLTC–TFE3 
LUC7L3-TFE3 
KHSRP-TFE3 
60-70 
10-20 
5-7 
* 
* 
* 
* 
Renal cell carcinoma associated with 
t(6;11) translocations 
t(6;11)(p21;q12) 
t(6;6)(p21;q11) 
MALAT1-TFEB 
KHDRBS2-TFEB 
90–100 
# 
Chromophobe renal cell carcinoma - 1 
- 2 
- 6 
-10 
- 13 
- 17 
- 21 
- 
- 
- 
- 
- 
- 
- 
 
 
 
70–90 
 
 
 
Renal medullary carcinoma t(1;22)(q41;q11) 
t(15;22)(q22;q11) 
t(11;22)(q21;q11) 
t(11;22)(q13;q11) 
SMARCB1-CAPN2 
SMARCB1-RORA 
SMARCB1-MAML2 
SMARCB1-MALAT1 
# 
#  
# 
# 
ALK translocation associate renal cell 
carcinoma 
b
 
t(2;1)(p23;q21) 
t(2;10)(p23;q22) 
TPM3-ALK  
VCL-ALK 
100 
# 
Wilms tumour i(17)(q10) 
i(7)(q10) 
- 
- 
* 
# 
Clear cell sarcoma of the kidney t(10;17)(q22;p13) YWHAE-NUTM2E 13-25 
Urothelial carcinoma Polysomy 3 
Polysomy 7 
Polysomy 17 
del(9)(p21) 
- 
- 
- 
CDKN2A 
 
80–94
c 
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t(4;7)(p16;q22) 
t(4;4)(p16;p16) 
t(12;16)(q13;p13) 
 
FGFR3-BAIAP2L1 
FGFR3-TACC3 
SCN8A-GRIN2A 
 
5-9 
3-6 
# 
Prostatic adenocarcinoma t(21;21)(q22;q22) 
t(21;16)(q22;q13) 
t(21;1)(q22;q32) 
t(21;8)(q22;q24) 
t(7;22)(p21;q22) 
t(17;22)(q21;q22) 
 
t(7;21)(p21;q22) 
t(7;1)(p21;q32) 
t(7;15)(p21;q21) 
t(7;7)(p21;q15) 
t(7;11)(p21;p15) 
t(7;14)(p21;q13) 
t(7;17)(p21;p13) 
 
t(1;1)(q32;q32) 
t(17;21)(q21;q22) 
t(17;17)(q21;q25) 
 
t(3;21)(q27;q22) 
t(3;1)(q27;q32) 
 
t(17;19)(q21;q13) 
t(3;8)(p25;q22) 
t(7;1)(q34;q32) 
 
del(10)(q23) 
TMPRSS2-ERG 
HERPUD1-ERG 
SLC45A3-ERG 
NDRG1-ERG 
ETV1-ERG 
ETV4-ERG 
 
TMPRSS2-ETV1 
SLC45A3-ETV1 
C15orf21-ETV1 
HNRPA2B1-ETV1 
ASCL3-ETV1 
EST14-ETV1 
HERVK17-ETV1 
 
TMPRSS2-ETV4 
CANT1-ETV4 
KLK2-ETV4 
 
TMPRSS2-ETV5 
SLC45A3-ETV5 
 
SLC45A3-ELK4 
ESRP1-RAF1 
SLC45A3-BRAF 
 
PTEN 
 
47–79 
 
 
* 
* 
 
 
 
 
7–10 
 
 
 
 
* 
* 
* 
 
* 
* 
 
* 
* 
* 
 
40-70 
Testicular germ cell tumour i(12p) - 67–83 
Skin 
Spitz nevi t(5;6)(q33;q22) 
t(6;6)(p22;q22) 
t(6;12)(q22;p11) 
t(6;15)(q22;q21) 
t(6;12)(q22;p13) 
t(6;12)(q22;q24) 
t(6;12)(q22;q24) 
t(6;10)(q22;q25) 
t(3;6)(q12;q22) 
 
t(2;2)(p23;p23)  
t(1;2)(q23;p23) 
 
t(1;17)(q23;p13) 
t(1;1)(q23;q22) 
 
t(10;14)(q11;q32) 
t(10;10)(q11;p11) 
 
t(7;19)(q34;q13) 
t(7;19)(q34;q13) 
 
t(2;7)(q37;q31) 
PWWP2A-ROS1 
HLA-A-ROS1 
PPFIBP1-ROS1 
MYO5A-ROS1 
ERC1-ROS1 
CLIP1-ROS1 
ZCCHC8-ROS1 
SHTN1-ROS1 
TFG-ROS1 
 
DCTN1-ALK  
TPM3-ALK 
 
TP53-NTRK1 
LMNA-NTRK1 
 
GOLGA5-RET 
KIF5B-RET 
 
CEP89-BRAF 
LSM14A-BRAF 
 
LRRFIP1-MET 
 
 
 
 
15–20 
 
 
 
 
 
11–15 
 
 
7–16 
 
 
3 
 
 
* 
* 
 
* 
Page 57 of 64 The Journal of Pathology: Clinical Research
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
Melanoma amp(11)(q13) 
amp(6)(p25)  
amp(6)(q23) 
 
t(1;7)(q32;q34) 
t(4;7)(q25;q34) 
t(7;7)(q33;q34) 
t(7;7)(q34;q34) 
t(7;7)(p22;q34) 
t(7;7)(q11;q34) 
t(7;7)(p13;q34) 
t(7;11)(q34;p15) 
t(7;7)(q22;q34) 
t(7;19)(q34;p13) 
 
t(7;7)(q22;q31) 
t(7;7)(q22;q31) 
 
t(3;8)(p25;q22) 
CCND1 
RREB1 
MYB 
 
SLC45A3-BRAF 
PAPSS1-BRAF 
TRIM24-BRAF 
AGK-BRAF 
MAD1L1-BRAF 
KCTD7-BRAF 
NUDCD3-BRAF 
SOX6-BRAF 
ZKSCAN5-BRAF 
PLIN3-BRAF 
 
ZKSCAN1-MET 
TRIM4-MET 
 
ESRP1-RAF1 
 
54–82
d 
 
 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
 
* 
* 
 
* 
Nervous system 
Oligodendrogliomas del(1)(p36), del(19)(q13) 
t(1;19)(q10;p10) 
- 
- 
77-92 
# 
Glioblastomas del(10)(q23) 
 
t(7;7)(q31;q31) 
t(4;4)(p16;p16) 
t(4;8)(p16;p11) 
t(3;?)(p27;?) 
t(7;7)(p11;p12) 
PTEN 
 
PTPRZ1-MET 
FGFR3-TACC3 
FGFR1-TACC3 
?-BCL6 
LANCL2- SEPT14 
43 
 
15-35 
5-8 
 
5 
* 
Angiocentric glioma t(6;6)(q23;q26) MYB-QKI 80 
Pilocytic astrocytoma t(7;7)(q34;q34) 
t(7;5)(q34;q35) 
t(9;6)(q21;q26) 
KIAA1549-BRAF 
RNF130-BRAF  
QKI-NTRK2 
64–73 
* 
* 
Medulloblastoma i(17q) 
t(1;19)(q23;p13) 
- 
E2A-PBX1 
30–50 
# 
Meningioma del(22)(q12) 
t(12;22)(p13;q12) 
t(1;19)(q21;q13.3) 
NF2 
MN1-ETV6 
- 
50-60 
# 
# 
Ependymoma -del(22)(q11) 
t(11;11)(q13;q13) 
t(2;14)(p23;q22) 
del(2)(p16p23) 
- 
C11orf95-RELA 
KTN1-ALK 
CCDC88A-ALK 
20–30 
71–80 
# 
# 
Extraventricular neurocytoma t(1;19)(q10;p10) - 17-20 
Papillary glioneuronal tumour t(9;17)(q31;q24) SLC44A1-PRKCA # 
 
Data Sources: http://cancer.sanger.ac.uk/cosmic; https://www.mycancergenome.org; http://www.genenames.org; 
http://atlasgeneticsoncology.org; http://cgap.nci.nih.gov/chromosomes; http://www.genecards.org; 
www.tumorfusions.org. 
* Too infrequent to estimate percentage, # limited report 
a: Higher incidence in radiation induced thyroid cancers 
b: 50% with sickle-cell trait 
c:  The UroVysion Bladder Cancer Kit (UroVysion Kit) is FDA approved and designed to detect aneuploidy for 
chromosomes 3, 7, 17, and loss of the 9p21 locus in urothelial tumours.  
d:  The Vysis Melanoma FISH Probe Kit is designed to detect copy number of the RREB1 (6p25), MYB (6q23), 
CCND1 (11q13) genes and of centromere 6 in melanocytic lesions.  
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Figure 2  
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Figure 3  
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Figure 4  
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Figure 5  
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Figure 6  
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